Disciplined Equity Management Inc. Buys Shares of 227 Danaher Co. (NYSE:DHR)

Disciplined Equity Management Inc. acquired a new position in shares of Danaher Co. (NYSE:DHR) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 227 shares of the conglomerate’s stock, valued at approximately $53,000.

Other hedge funds also recently bought and sold shares of the company. Wellington Management Group LLP raised its holdings in shares of Danaher by 18.6% in the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after purchasing an additional 3,905,449 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Danaher by 6.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 8,183,501 shares of the conglomerate’s stock valued at $2,030,327,000 after purchasing an additional 502,868 shares during the period. Northern Trust Corp boosted its holdings in shares of Danaher by 1.7% in the third quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock valued at $2,009,789,000 after acquiring an additional 134,905 shares during the period. Flossbach Von Storch AG grew its position in Danaher by 1.8% during the 4th quarter. Flossbach Von Storch AG now owns 4,601,351 shares of the conglomerate’s stock worth $1,064,477,000 after purchasing an additional 82,672 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Danaher by 13.2% during the third quarter. Invesco Ltd. now owns 4,070,455 shares of the conglomerate’s stock worth $1,009,880,000 after buying an additional 473,693 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Bank of America lifted their price objective on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday. Robert W. Baird raised their price objective on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Citigroup raised their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, KeyCorp boosted their price objective on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Six analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $270.00.

Danaher Trading Down 1.1 %

NYSE:DHR traded down $2.70 on Wednesday, hitting $250.41. 3,064,441 shares of the stock were exchanged, compared to its average volume of 2,783,958. The stock has a fifty day moving average of $249.00 and a 200-day moving average of $230.78. The stock has a market cap of $185.44 billion, a PE ratio of 39.19, a PEG ratio of 3.96 and a beta of 0.83. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same period in the previous year, the company posted $2.36 earnings per share. Danaher’s revenue was down 2.6% compared to the same quarter last year. As a group, equities analysts expect that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be issued a $0.27 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a yield of 0.43%. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s dividend payout ratio is currently 16.90%.

Insider Buying and Selling at Danaher

In related news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Teri List sold 3,289 shares of Danaher stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the sale, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Georgeann Couchara sold 2,622 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Insiders have sold 32,957 shares of company stock valued at $8,265,802 over the last three months. 10.90% of the stock is owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.